Short Interest in iSpecimen Inc. (NASDAQ:ISPC) Drops By 56.2%

iSpecimen Inc. (NASDAQ:ISPC) saw a large drop in short interest in March. As of March 31st, there was short interest totalling 34,900 shares, a drop of 56.2% from the March 15th total of 79,700 shares. Based on an average daily volume of 803,300 shares, the short-interest ratio is presently 0.0 days. Currently, 4.2% of the company’s stock are sold short.

iSpecimen Trading Down 3.9 %

NASDAQ ISPC opened at $1.22 on Wednesday. The company has a market cap of $1.17 million, a P/E ratio of -0.06 and a beta of 1.77. The company has a fifty day simple moving average of $1.49 and a 200 day simple moving average of $2.91. iSpecimen has a 12-month low of $1.02 and a 12-month high of $11.80.

iSpecimen (NASDAQ:ISPC) last posted its earnings results on Monday, April 14th. The company reported ($6.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($4.00) by ($2.28). The business had revenue of $1.48 million during the quarter, compared to analyst estimates of $2.98 million. iSpecimen had a negative return on equity of 139.25% and a negative net margin of 91.66%.

Hedge Funds Weigh In On iSpecimen

A hedge fund recently bought a new stake in iSpecimen stock. Bridgeway Capital Management LLC bought a new stake in shares of iSpecimen Inc. (NASDAQ:ISPC) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 21,800 shares of the company’s stock, valued at approximately $58,000. Bridgeway Capital Management LLC owned about 2.27% of iSpecimen at the end of the most recent reporting period. Hedge funds and other institutional investors own 13.62% of the company’s stock.

About iSpecimen

iSpecimen Inc provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers.